secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001753926-25-000652
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 3.02, 4.01, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Channel Therapeutics to merge with LNHC in reverse merger; Ligand to own ~55%
-----------------------------------------------------------------------------

- LNHC valued at $67M; Channel at $15M; combined entity renamed Pelthos Therapeutics Inc.
- Post-closing ownership: legacy CHRO 7.7%, Ligand 55.1%, other PIPE investors 37.2%.
- PIPE financing of $50.1M from Ligand, Nomis Bay, others; convertible at $1.00/share.
- New board includes Scott Plesha (CEO), Francis Knuettel II (CFO); lock-up until Dec 31, 2025.
- Auditor changed from Marcum to CBIZ; material weaknesses in internal controls continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625000652/0001753926-25-000652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625000652/g084777_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer